
Gamida's Omisirge therapy FDA approved for blood cancer treatment.
The US FDA has approved the use of Gamida Cell's cell therapy, Omisirge, for reducing the risk of infection in patients undergoing treatment for blood cancer. The therapy is given as a single intravenous dose and is made using donor stem cells obtained from umbilical cord blood. The approval is based on a late-stage study that showed a quicker recovery of neutrophils in patients taking Omisirge, compared with those who received umbilical cord blood transplantation.
